Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2h-tetrazole-2-ethanol, Alpha-(2-chlorophenyl)-, Carbamate (ester), (alphar)-
2. Carbamic Acid (r)-(+)-1-(2-chlorophenyl)-2-(2h-tetrazol-2-yl)ethyl Ester
3. Xcopri
4. Ykp-3089
5. Ykp3089
1. Xcopri
2. 913088-80-9
3. Cenobamate [inn]
4. Ykp3089
5. Ykp-3089
6. P85x70rzws
7. [(1r)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] Carbamate
8. Carbamic Acid (r)-(+)-1-(2-chlorophenyl)-2-(2h-tetrazol-2-yl)ethyl Ester
9. Ontozry
10. Unii-p85x70rzws
11. Xcopri (tn)
12. Cenobamate [mi]
13. Ykp-3089 Cenobamate
14. Cenobamate (usan/inn)
15. Cenobamate [usan:inn]
16. Cenobamate [usan]
17. Cenobamate [who-dd]
18. Schembl1682643
19. Cenobamate [orange Book]
20. Chembl3989949
21. Gtpl10773
22. Ykp3089ykp3089
23. Dtxsid001027948
24. Ex-a3604
25. 2h-tetrazole-2-ethanol, Alpha-(2-chlorophenyl)-, 2-carbamate, (alphar)-
26. Db06119
27. 2h-tetrazole-2-ethanol, Alpha-(2-chlorophenyl)-, Carbamate (ester), (alphar)-
28. Hy-17607
29. Cs-0014686
30. D11150
31. Q27286352
32. (1r)-1-(2-chlorophenyl)-2-(tetrazol-yl)ethyl)carbamate
33. (1r)-1-(2-chlorophenyl)-2-(2h-1,2,3,4-tetrazol-2-yl)ethyl Carbamate
34. (1r)-1-(2-chlorophenyl)-2-(2h-tetrazol-2-yl)ethyl Carbamate
35. 2h-tetrazole-2-ethanol, .alpha.-(2-chlorophenyl)-, 2-carbamate, (.alpha.r)-
36. 2h-tetrazole-2-ethanol, .alpha.-(2-chlorophenyl)-, Carbamate (ester), (.alpha.r)-
37. 2h-tetrazole-2-ethanol, Alpha-(2-chlorophenyl)-, Yl)ethyl)carbamate Carbamate (ester), (.alpha.r)-
Molecular Weight | 267.67 g/mol |
---|---|
Molecular Formula | C10H10ClN5O2 |
XLogP3 | 1.5 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 5 |
Exact Mass | 267.0523023 g/mol |
Monoisotopic Mass | 267.0523023 g/mol |
Topological Polar Surface Area | 95.9 Ų |
Heavy Atom Count | 18 |
Formal Charge | 0 |
Complexity | 293 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Cenobamate is indicated for the treatment of partial onset seizures in adults.
Adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.
The mechanism of cenobamate is unknown, however it modulates GABAA and inhibit voltage gated sodium channels. Cenobamate is given once daily and so it has a long duration of action. The therapeutic window is wide as doses of 750mg can be well tolerated. Patients should be counselled regarding the risk of DRESS syndrome, QT interval shortening, suicidal behavior, and neurological adverse effects.
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
N03AX
N - Nervous system
N03 - Antiepileptics
N03A - Antiepileptics
N03AX - Other antiepileptics
N03AX25 - Cenobamate
Absorption
Cenobamate is 88% orally bioavailable with a Tmax of 1-4 hours. A high fat meal does not significantly impact the pharmacokinetics of cenobamate.
Route of Elimination
Cenobamate is 87.8% eliminated in the urine and 5.2% in the feces.
Volume of Distribution
The apparent volume of distribution of cenobamate is 40-50L.
Clearance
The apparent oral clearance of cenobamate is 0.45-0.63L/h for a 100-400mg/day dose.
Data regarding the metabolism of cenobamate is lacking, however it is mostly glucuronidated by UGT2B7 and UGT2B4 or oxidized by a number of cytochromes.
The terminal half life of cenobamate is 50-60h.
Cenobamate inhibits voltage gated sodium channels and is a positive GABAA modulator. However, the exact mechanism of action remains unknown. Inhibition of voltage gated sodium channels increases the threshold for generating action potentials and decreases the number of action potentials.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40667
Submission : 2024-10-28
Status : Active
Type : II
Date of Issue : 2024-04-03
Valid Till : 2027-01-21
Written Confirmation Number : WC-0493
Address of the Firm :
NDC Package Code : 42765-071
Start Marketing Date : 2024-10-28
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (15kg/15kg)
Marketing Category : BULK INGREDIENT
Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-13
Pay. Date : 2023-09-28
DMF Number : 38780
Submission : 2023-09-21
Status : Active
Type : II
NDC Package Code : 73435-036
Start Marketing Date : 2023-12-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (60kg/60kg)
Marketing Category : BULK INGREDIENT
Maithri Drugs: Delivering Trusted, High-Quality APIs to 35+ Countries with Innovation, Compliance, and Excellence.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-08
Pay. Date : 2023-09-29
DMF Number : 38751
Submission : 2023-09-20
Status : Active
Type : II
NDC Package Code : 81666-005
Start Marketing Date : 2023-09-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41155
Submission : 2025-03-28
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-13
Pay. Date : 2023-09-15
DMF Number : 38814
Submission : 2023-09-26
Status : Active
Type : II
NDC Package Code : 59651-881
Start Marketing Date : 2023-11-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40667
Submission : 2024-10-28
Status : Active
Type : II
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Complete
Rev. Date : 2023-11-13
Pay. Date : 2023-09-28
DMF Number : 38780
Submission : 2023-09-21
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-11-13
Pay. Date : 2023-09-15
DMF Number : 38814
Submission : 2023-09-26
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-11-08
Pay. Date : 2023-09-29
DMF Number : 38751
Submission : 2023-09-20
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41155
Submission : 2025-03-28
Status : Active
Type : II
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Date of Issue : 2024-04-03
Valid Till : 2027-01-21
Written Confirmation Number : WC-0493
Address of the Firm : Unit-IV, Plot No: 34B, 40B & 60B, J.N. Pharma City, Thanam (V), Parawada (M), An...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
NDC Package Code : 42765-071
Start Marketing Date : 2024-10-28
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (15kg/15kg)
Marketing Category : BULK INGREDIENT
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
NDC Package Code : 73435-036
Start Marketing Date : 2023-12-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (60kg/60kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59651-881
Start Marketing Date : 2023-11-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 81666-005
Start Marketing Date : 2023-09-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 60240-0272
Start Marketing Date : 2024-10-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 74436-0223
Start Marketing Date : 2020-03-12
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.
About the Company : Lee Pharma Ltd, established in 1997, is a research-driven pharmaceutical company focused on developing, synthesizing, and commercializing high-quality APIs, intermediates, and fini...
Maithri Drugs: Delivering Trusted, High-Quality APIs to 35+ Countries with Innovation, Compliance, and Excellence.
About the Company : Maithri Drugs is one of India's fastest growing pharmaceutical companies, strategically focused on Active Pharmaceutical Ingredients (APIs). Backed by a strong R&D foundation, we h...
About the Company : Aptra Synthesis Private Limited, is a reliable and vertically integrated manufacturer of APIs and intermediates, boasting state-of-the-art manufacturing facilities that adhere to G...
About the Company : Bajaj Healthcare Ltd. is a company established in 1993, services various Pharmaceuticals, Nutraceutical and Food industries globally with a spirit of scrupulousness. Bajaj Healt...
About the Company : Medichem is an indepently-owned company based in Barcelona. Founded in 1972 and with more than 45 years, Medichem has been engaged in the process development and manufacture of Act...
About the Company : Founded in 2003, Hyderabad-based MSN Labs is one of the fastest-growing research-based pharmaceutical company in India. Boasting a diverse product portfolio, with multiple products...
About the Company : Established in 1984, R L Fine Chem Pvt. Ltd. is one of the fastest growing API companies, with a leadership position in several APIs such as antihistamines, antidepressants and mus...
About the Company : Sekhmet Pharmaventures Pvt. Ltd., an Indian subsidiary of Gamot API Pte. Ltd., is backed by prominent private equity firms including PAG, CX Partners, and Samara Capital. The compa...
About the Company : Hope Chem is dedicated to manufacturing, marketing, and CMO service of Active Pharmaceutical Ingredients (APIs), Intermediates, and Specialty Chemicals since the year 2010. Current...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Bajaj is working on a generic version of the anti-seizure medication, cenobamate, as part of its efforts to expand its portfolio in the epilepsy treatment market.
Lead Product(s): Cenobamate,Inapplicable
Therapeutic Area: Neurology Brand Name: Cenobamate-Generic
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 20, 2025
Lead Product(s) : Cenobamate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bajaj Healthcare Limited Secures SEC-CDSCO Nod for Phase III Trials of Cenobamate
Details : Bajaj is working on a generic version of the anti-seizure medication, cenobamate, as part of its efforts to expand its portfolio in the epilepsy treatment market.
Product Name : Cenobamate-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 20, 2025
Details:
Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.
Lead Product(s): Cenobamate,Inapplicable
Therapeutic Area: Neurology Brand Name: Xcopri
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: SK Biopharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 20, 2025
Lead Product(s) : Cenobamate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : SK Biopharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Dong-A ST Seeks Approval for Epilepsy Drug Cenobamate in South Korea
Details : Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.
Product Name : Xcopri
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 20, 2025
Details:
Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.
Lead Product(s): Cenobamate,Inapplicable
Therapeutic Area: Neurology Brand Name: Xcopri
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: SK Biopharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 10, 2024
Lead Product(s) : Cenobamate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : SK Biopharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Cenobamate Demonstrates Clinical Efficacy and Safety across Korea, China and Japan
Details : Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.
Product Name : Xcopri
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 10, 2024
Details:
Ignis Therapeutics holds exclusive commercialization rights to Xcopri (cenobamate), is an antiseizure medication for epilepsy in Greater China.
Lead Product(s): Cenobamate,Inapplicable
Therapeutic Area: Neurology Brand Name: Xcopri
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: SK Biopharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 04, 2024
Lead Product(s) : Cenobamate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : SK Biopharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
SK biopharmaceuticals files NDA for Cenobamate in China Through Ignis Therapeutics
Details : Ignis Therapeutics holds exclusive commercialization rights to Xcopri (cenobamate), is an antiseizure medication for epilepsy in Greater China.
Product Name : Xcopri
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 04, 2024
Details:
Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.
Lead Product(s): Cenobamate,Inapplicable
Therapeutic Area: Neurology Brand Name: Xcopri
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 04, 2024
Lead Product(s) : Cenobamate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
XCOPRI Gets FDA Approval for Alternate Methods of Oral or Nasogastric Administration
Details : Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.
Product Name : Xcopri
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 04, 2024
Details:
Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.
Lead Product(s): Cenobamate,Inapplicable
Therapeutic Area: Neurology Brand Name: Xcopri
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: SK Biopharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 08, 2024
Lead Product(s) : Cenobamate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : SK Biopharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
SK Biopharm and Eurofarma Submit NDA for Epilepsy Drug in Brazil
Details : Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.
Product Name : Xcopri
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 08, 2024
Details:
Undisclosed
Lead Product(s): Cenobamate,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 19, 2024
Lead Product(s) : Cenobamate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 19, 2024
Details:
Undisclosed
Lead Product(s): Cenobamate,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 30, 2024
Lead Product(s) : Cenobamate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 30, 2024
Details:
Undisclosed
Lead Product(s): Cenobamate,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 11, 2024
Lead Product(s) : Cenobamate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 11, 2024
Details:
Xcopri (cenobamate) is a positive allosteric modulator of the GABAA ion channel. It is approved as adjunctive therapy in the management of partial-onset seizures in adults with epilepsy.
Lead Product(s): Cenobamate,Inapplicable
Therapeutic Area: Neurology Brand Name: Xcopri
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 22, 2024
Lead Product(s) : Cenobamate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Endo's Paladin Labs Announces Launch of XCOPRI® (cenobamate tablets) in Canada
Details : Xcopri (cenobamate) is a positive allosteric modulator of the GABAA ion channel. It is approved as adjunctive therapy in the management of partial-onset seizures in adults with epilepsy.
Product Name : Xcopri
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 22, 2024
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
89
PharmaCompass offers a list of Cenobamate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cenobamate manufacturer or Cenobamate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cenobamate manufacturer or Cenobamate supplier.
PharmaCompass also assists you with knowing the Cenobamate API Price utilized in the formulation of products. Cenobamate API Price is not always fixed or binding as the Cenobamate Price is obtained through a variety of data sources. The Cenobamate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cenobamate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cenobamate, including repackagers and relabelers. The FDA regulates Cenobamate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cenobamate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cenobamate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cenobamate supplier is an individual or a company that provides Cenobamate active pharmaceutical ingredient (API) or Cenobamate finished formulations upon request. The Cenobamate suppliers may include Cenobamate API manufacturers, exporters, distributors and traders.
click here to find a list of Cenobamate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cenobamate DMF (Drug Master File) is a document detailing the whole manufacturing process of Cenobamate active pharmaceutical ingredient (API) in detail. Different forms of Cenobamate DMFs exist exist since differing nations have different regulations, such as Cenobamate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cenobamate DMF submitted to regulatory agencies in the US is known as a USDMF. Cenobamate USDMF includes data on Cenobamate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cenobamate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cenobamate suppliers with USDMF on PharmaCompass.
A Cenobamate written confirmation (Cenobamate WC) is an official document issued by a regulatory agency to a Cenobamate manufacturer, verifying that the manufacturing facility of a Cenobamate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cenobamate APIs or Cenobamate finished pharmaceutical products to another nation, regulatory agencies frequently require a Cenobamate WC (written confirmation) as part of the regulatory process.
click here to find a list of Cenobamate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cenobamate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cenobamate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cenobamate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cenobamate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cenobamate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cenobamate suppliers with NDC on PharmaCompass.
Cenobamate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cenobamate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cenobamate GMP manufacturer or Cenobamate GMP API supplier for your needs.
A Cenobamate CoA (Certificate of Analysis) is a formal document that attests to Cenobamate's compliance with Cenobamate specifications and serves as a tool for batch-level quality control.
Cenobamate CoA mostly includes findings from lab analyses of a specific batch. For each Cenobamate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cenobamate may be tested according to a variety of international standards, such as European Pharmacopoeia (Cenobamate EP), Cenobamate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cenobamate USP).